Skip to content

Study · Randomized controlled trial · n = 94 · 1995

8 results

Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation.

Sung JJ, Chung SC, Yung MY, Lai CW, Lau JY, Lee YT, Leung VK, Li MK, Li AK

Lancet (London, England)1 Dec 1995Cited by 127 (Europe PMC)

PMID8551824 (opens in a new tab)DOI10.1016/s0140-6736(95)92840-5 (opens in a new tab)PepBankPUB-08551824
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with variceal bleeding, control occurred in 45 of 47 with octreotide plus ligation versus 44 of 47 with ligation alone (p = 1.0).

    In plain wordsIn patients with variceal bleeding, bleeding control was numerically higher with added octreotide than ligation alone, without statistical significance.

    Peptide
    Octreotide
    Outcome
    IncreaseBleeding control
    Study

    n = 94

    Comparator
    Endoscopic variceal ligation alone
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    50 micrograms bolus, then 50 micrograms per h · intravenous · 5 daysAs given in this study (human).

    Measurements

    Patients with bleeding controlled
    45 of 47 patients
    octreotide plus variceal ligation
    Patients with bleeding controlled
    44 of 47 patients
    variceal ligation alone
    P value
    1
    bleeding control

    Source sentences

    Summary
    Bleeding was controlled in 44 of 47 patients who received variceal ligation alone and in 45 of 47 who received combined treatment (p = 1.0).
    2 context sentences
    Summary · context
    100 consecutive patients admitted with endoscopically confirmed oesophageal varices and active bleeding or signs of recent haemorrhage were randomly assigned endoscopic variceal ligation alone or octreotide (50 micrograms intravenous bolus injection followed by intravenous infusion at 50 micrograms…
    Summary · context
    Three patients in each group were excluded.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients after variceal ligation, recurrent bleeding occurred in four (9% [3-21]) with octreotide versus 18 (38% [24-52]) with ligation alone (p = 0.0007).

    In plain wordsIn patients after variceal ligation, added octreotide reduced recurrent bleeding versus ligation alone.

    Peptide
    Octreotide
    Outcome
    DecreaseRecurrent bleeding
    Study

    n = 94

    Comparator
    Endoscopic variceal ligation alone
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    50 micrograms bolus, then 50 micrograms per h · intravenous · 5 daysAs given in this study (human).

    Measurements

    Patients with recurrent bleeding
    4 patients
    octreotide plus variceal ligation
    Recurrent bleeding rate
    9 percent
    octreotide plus variceal ligation
    95 percent CI of recurrent bleeding rate
    3 to 21 percent
    octreotide plus variceal ligation
    Patients with recurrent bleeding
    18 patients
    variceal ligation alone
    Recurrent bleeding rate
    38 percent
    variceal ligation alone
    95 percent CI of recurrent bleeding rate
    24 to 52 percent
    variceal ligation alone
    P value
    0.0007
    recurrent bleeding

    Source sentences

    Summary
    Recurrent bleeding was documented in 18 (38% [24-52]) patients who received variceal ligation alone and in four (9% [3-21] who received combined treatment (p = 0.0007).
    2 context sentences
    Summary · context
    100 consecutive patients admitted with endoscopically confirmed oesophageal varices and active bleeding or signs of recent haemorrhage were randomly assigned endoscopic variceal ligation alone or octreotide (50 micrograms intravenous bolus injection followed by intravenous infusion at 50 micrograms…
    Summary · context
    Three patients in each group were excluded.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients after variceal ligation, added octreotide lowered rebleeding risk to 0.22 [0.08-0.60] relative to ligation alone.

    In plain wordsIn patients after variceal ligation, added octreotide lowered rebleeding risk versus ligation alone.

    Peptide
    Octreotide
    Outcome
    DecreaseRelative risk of rebleeding
    Study

    n = 94

    Comparator
    Endoscopic variceal ligation alone
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    50 micrograms bolus, then 50 micrograms per h · intravenous · 5 daysAs given in this study (human).

    Measurements

    Relative risk of rebleeding
    0.22
    octreotide plus variceal ligation versus variceal ligation alone
    Confidence interval of relative risk
    0.08 to 0.6
    octreotide plus variceal ligation versus variceal ligation alone

    Source sentences

    Summary
    The relative risk of rebleeding was lower (0.22 [0.08-0.60]) in the combined therapy group.
    2 context sentences
    Summary · context
    100 consecutive patients admitted with endoscopically confirmed oesophageal varices and active bleeding or signs of recent haemorrhage were randomly assigned endoscopic variceal ligation alone or octreotide (50 micrograms intravenous bolus injection followed by intravenous infusion at 50 micrograms…
    Summary · context
    Three patients in each group were excluded.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with variceal bleeding, one patient with octreotide plus ligation versus ten with ligation alone required balloon tamponade (p = 0.0039).

    In plain wordsIn patients with variceal bleeding, added octreotide reduced balloon tamponade requirements versus ligation alone.

    Peptide
    Octreotide
    Outcome
    DecreaseBalloon tamponade requirement
    Study

    n = 94

    Comparator
    Endoscopic variceal ligation alone
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    50 micrograms bolus, then 50 micrograms per h · intravenous · 5 daysAs given in this study (human).

    Measurements

    Patients needing balloon tamponade
    1 patients
    octreotide plus variceal ligation
    Patients needing balloon tamponade
    10 patients
    variceal ligation alone
    P value
    0.0039
    balloon tamponade

    Source sentences

    Summary
    Ten patients in the variceal ligation group and one in the combined therapy group required balloon tamponade for massive haematesis and haemodynamic instability (p = 0.0039).
    2 context sentences
    Summary · context
    100 consecutive patients admitted with endoscopically confirmed oesophageal varices and active bleeding or signs of recent haemorrhage were randomly assigned endoscopic variceal ligation alone or octreotide (50 micrograms intravenous bolus injection followed by intravenous infusion at 50 micrograms…
    Summary · context
    Three patients in each group were excluded.
  5. 05HumanRandomized controlled trialSafety outcome

    In patients after variceal ligation, in-hospital mortality was 9% with added octreotide versus 19% with ligation alone, without statistical significance.

    In plain wordsIn patients after variceal ligation, in-hospital mortality was numerically lower with added octreotide than ligation alone, without statistical significance.

    Peptide
    Octreotide
    Outcome
    DecreaseIn-hospital mortality
    Study

    n = 94

    Comparator
    Endoscopic variceal ligation alone
    Outcome group
    Mortality · Gastrointestinal
    Studied dose
    50 micrograms bolus, then 50 micrograms per h · intravenous · 5 daysAs given in this study (human).

    Measurements

    In-hospital mortality
    9 percent
    octreotide plus variceal ligation
    In-hospital mortality
    19 percent
    variceal ligation alone

    Source sentences

    Summary
    The in-hospital and 30-day mortality rates were higher in the variceal ligation group than in the combined therapy group (19 vs 9% and 23 vs 11%), but the differences did not reach significance.
    2 context sentences
    Summary · context
    100 consecutive patients admitted with endoscopically confirmed oesophageal varices and active bleeding or signs of recent haemorrhage were randomly assigned endoscopic variceal ligation alone or octreotide (50 micrograms intravenous bolus injection followed by intravenous infusion at 50 micrograms…
    Summary · context
    Three patients in each group were excluded.
  6. 06HumanRandomized controlled trialSafety outcome

    In patients after variceal ligation, 30-day mortality was 11% with added octreotide versus 23% with ligation alone, without statistical significance.

    In plain wordsIn patients after variceal ligation, 30-day mortality was numerically lower with added octreotide than ligation alone, without statistical significance.

    Peptide
    Octreotide
    Outcome
    Decrease30-day mortality
    Study

    n = 94

    Comparator
    Endoscopic variceal ligation alone
    Outcome group
    Mortality · Gastrointestinal
    Studied dose
    50 micrograms bolus, then 50 micrograms per h · intravenous · 5 daysAs given in this study (human).

    Measurements

    30-day mortality
    11 percent
    octreotide plus variceal ligation
    30-day mortality
    23 percent
    variceal ligation alone

    Source sentences

    Summary
    The in-hospital and 30-day mortality rates were higher in the variceal ligation group than in the combined therapy group (19 vs 9% and 23 vs 11%), but the differences did not reach significance.
    2 context sentences
    Summary · context
    100 consecutive patients admitted with endoscopically confirmed oesophageal varices and active bleeding or signs of recent haemorrhage were randomly assigned endoscopic variceal ligation alone or octreotide (50 micrograms intravenous bolus injection followed by intravenous infusion at 50 micrograms…
    Summary · context
    Three patients in each group were excluded.
  7. 07HumanRandomized controlled trialSafety outcome

    In patients after variceal ligation, added octreotide had an in-hospital mortality relative risk of 0.5 [0.04=5.3] versus ligation alone.

    In plain wordsAfter variceal ligation, in-hospital mortality risk was numerically lower with added octreotide, without statistical significance.

    Peptide
    Octreotide
    Outcome
    DecreaseIn-hospital mortality relative risk
    Study

    n = 94

    Comparator
    Endoscopic variceal ligation alone
    Outcome group
    Mortality · Gastrointestinal
    Studied dose
    50 micrograms bolus, then 50 micrograms per h · intravenous · 5 daysAs given in this study (human).

    Measurements

    In-hospital mortality relative risk
    0.5
    octreotide plus variceal ligation versus variceal ligation alone
    Confidence interval of in-hospital mortality relative risk
    0.04 to 5.3
    octreotide plus variceal ligation versus variceal ligation alone

    Source sentences

    Summary
    The relative risks of in-hospital (0.5 [0.04=5.3]) and 30-day (0.45 [0.17-1.2]) mortality were lower in the combined therapy group.
    2 context sentences
    Summary · context
    100 consecutive patients admitted with endoscopically confirmed oesophageal varices and active bleeding or signs of recent haemorrhage were randomly assigned endoscopic variceal ligation alone or octreotide (50 micrograms intravenous bolus injection followed by intravenous infusion at 50 micrograms…
    Summary · context
    Three patients in each group were excluded.
  8. 08HumanRandomized controlled trialSafety outcome

    In patients after variceal ligation, added octreotide had a 30-day mortality relative risk of 0.45 [0.17-1.2] versus ligation alone.

    In plain wordsAfter variceal ligation, 30-day mortality risk was numerically lower with added octreotide, without statistical significance.

    Peptide
    Octreotide
    Outcome
    Decrease30-day mortality relative risk
    Study

    n = 94

    Comparator
    Endoscopic variceal ligation alone
    Outcome group
    Mortality · Gastrointestinal
    Studied dose
    50 micrograms bolus, then 50 micrograms per h · intravenous · 5 daysAs given in this study (human).

    Measurements

    30-day mortality relative risk
    0.45
    octreotide plus variceal ligation versus variceal ligation alone
    Confidence interval of 30-day mortality relative risk
    0.17 to 1.2
    octreotide plus variceal ligation versus variceal ligation alone

    Source sentences

    Summary
    The relative risks of in-hospital (0.5 [0.04=5.3]) and 30-day (0.45 [0.17-1.2]) mortality were lower in the combined therapy group.
    2 context sentences
    Summary · context
    100 consecutive patients admitted with endoscopically confirmed oesophageal varices and active bleeding or signs of recent haemorrhage were randomly assigned endoscopic variceal ligation alone or octreotide (50 micrograms intravenous bolus injection followed by intravenous infusion at 50 micrograms…
    Summary · context
    Three patients in each group were excluded.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT06085976

Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.

Clinica Universidad de Navarra, Universidad de Navarran = 6214 Aug 2023 to est. 30 Nov 2025

Hepatic Carcinoma · Hepatic Metastasis

Trial pageClinicalTrials.govUpdated 17 Oct 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.